Abstract | After decades of research, immunotherapies for cancer are demonstrating increasing success. These agents can amplify existent antitumour immunity or induce durable antitumour immune responses in a wide array of cancers. The spectrum of immunotherapeutics is broad, spanning monoclonal antibodies and their derivatives, tumour vaccines, and adoptive therapies using T cells and natural killer cells. Only a small number of immunotherapies have been tested in paediatric cancers, but impressive antitumour effects have already been observed. Mononclonal antibodies targeting GD2 that induce antibody-dependent cell-mediated cytotoxicity improve survival in high-risk neuroblastoma. Bi-specific monoclonal antibodies that simultaneously target CD19 and activate T cells can induce remission in acute B-cell lymphoblastic leukaemia (B-ALL) and adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors targeting CD19 induce impressive responses in B-ALL. Efforts are underway to generate and test new immunotherapies in a wider array of paediatric cancers. Major challenges include a need to identify immunotherapy targets on the most lethal childhood cancers, to expand availability of technology-intense platforms, such as adoptive cell therapy, to optimize management of novel toxicities associated with this new class of cancer therapies and to determine how best to incorporate these therapies into standard treatment paradigms.
Introduction
Impressive survival gains for childhood cancer occurred from 1975 to 1995, but survival rates have changed little in the past two decades. 1 Cytotoxic chemotherapy medi ates high response rates in most paediatric cancers and multiagent cytotoxic regimens improved survival in many settings; however, chemoresistance and toxicities associated with increasing dose intensity are barriers to continued progress. The molecular revolution in onco logy has spawned development of an impressive array of targeted therapeutics for adult cancers, but genomic analyses of paediatric tumours has thus far identified few targetable mutations. Immunotherapies have shown increasing promise in the treatment of adult cancer and a small but increasing body of evidence suggests that immunotherapy could improve outcomes for child hood cancers as well. [2] [3] [4] Emerging evidence demonstrat ing that immunebased therapies are effective against chemo resistant cancer cells, leads to the prediction that immunotherapies could prove effective for diseases not currently curable with cytotoxics and could be admin istered in combination with cytotoxics to improve out comes. Furthermore, given the prevalence and extent of longterm morbidity associated with cytotoxic regi mens required for cure of childhood cancer, the pros pect that immunotherapy could enable reduction in dose intensity of toxic agents, and thus diminish longterm morbid ity for cancer survivors, is compelling. We review immunotherapies with established efficacy in paediat ric cancers as well as immunotherapies currently under study or likely to be studied in the near future. We also discuss the emerging science driving this rapidly moving field and highlight the most pressing challenges that must be overcome for continued progress in this arena.
Graft-versus-tumour effects after transplantation
Allogeneic haematopoietic stemcell transplantation (alloHSCT) can cure paediatric patients with leukae mia who do not respond to standard frontline regi mens or who experience recurrence. Although initially intended as a rescue therapy following myeloablative chemotherapy or radiation, it is now well established that immunoreactivity-termed graftversusleukaemia (GVL)-contributes to therapeutic benefit. Infusion of donor lymphocytes (DLI) to patients with leukaemia recurrence after alloHSCT can induce remissions as a single therapeutic manoeuvre, although DLI therapy is often associated with offtumour toxic effects in the form of graftversushost disease (GVHD). 5 T cells mediate a major component of the GVL effect, as demonstrated by higher leukaemia relapse rates in recipients of Tcell depleted grafts and reduced relapse rates in patients with GVHD. Ongoing research seeks to enhance GVL with out GVHD. One area of focus includes adoptive transfer of donorderived T cells with greater tumour specificity and less specificity to nonmalignant tissues, which is discussed later.
Another approach is to augment the potency of GVL mediated by natural killer (NK) cells. Seminal studies in murine models have demonstrated that NK cells do not induce, and may actually diminish, GVHD. 6 Because NK cells are regulated by inhibitory signals delivered follow ing engagement of killer immunoglobulin receptors (KIR) to specific HLA alleles (Figure 1 ), donor recipient pairs can be selected with more or less NK inhibitory signal ling. 7 Early observations showed that in AML, 20 donor recipient pairs with HLAC or HLABw4 mismatch (such as KIR ligand mismatch) had a 0% probability of relapse at 5 years, compared with a 75% relapse rate in the 37 patients with KIR ligand compatible donors. 6 KIR ligand mismatch posed no greater risk of GVHD following Tcell depleted haploidentical HSCT. 6 Some subsequent studies, however, did not confirm these initial observa tions, and further scrutiny ultimately revealed the com plexity in this system. 8 For instance, alloreactive T cells diminish NK reactivity after alloHSCT, and thus KIR ligand mismatch has a lesspotent effect in Tcell replete HSCT. 9 Furthermore, knowledge of specific inhibitory KIR-KIR ligand interactions for some alleles has contin ued to evolve resulting in modifications to the original classification scheme. Furthermore, other inhibitory and activating receptors including CD94/NKGD2A, KIR2DS1 and activating B/x haplotypes are now believed to signifi cantly modulate NK cell activity. 7, 8, 10 Thus optimal donor selection requires more than evaluation for KIR ligand mismatch. Despite these complexities, several studies that have included paediatric patients have demonstrated improved outcomes using donors bearing a genotype that predicts NK activation following Tcell depleted alloHSCT, 7, 8 and studies are underway to further improve outcomes by optimizing donor selection algorithms.
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Some groups are attempting to improve NK cell immune reconstitution following HSCT by depleting the graft of T cells and CD19 + B cells, but leaving NK pro genitors intact. [12] [13] [14] Others are employing adoptive trans fer of autologous and allogeneic NK cells to amplify the antitumour effects of this lymphocyte subset. In the first report, remission was observed in 5 of 19 adult patients treated with haploidentical NK cells plus recombinant human interleukin2 (rhIL2) without HSCT. 15 A study in children wherein 10 patients with AML in first remis sion received haploidentical NK cells plus rhIL2 reported a 100% estimated 2year eventfree survival (EFS). 16 Key points ■ Graft-versus-leukaemic effects improve survival following allogeneic stem cell transplantation for childhood leukaemia, and provide proof-of-principle that immune mediated effects can eradicate chemoresistant cancer cells ■ Anti-GD2 monoclonal antibodies can be curative when administered in the setting of minimal residual disease for neuroblastoma, and efficacy requires optimal induction of antibody-dependent cell-mediated cytotoxicity (ADCC) ■ In general, tumour vaccines do not regress established tumours, but can diminish tumour growth or recurrence; randomized studies will be needed to define their efficacy in paediatric cancer ■ Adoptive T-cell immunotherapies have demonstrated efficacy against Epstein-Barr virus-associated lymphoproliferative neoplasms and impressive results have been reported using genetically engineered T cells to treat paediatric leukemia ■ Expansion of the immunotherapeutic armamentarium for paediatric cancers hinges on identification of new immune targets ■ Toxicity associated with immunotherapies is distinct from toxicity associated with cytotoxic agents and small-molecule kinase inhibitors; most common toxic effects include cytokine-release syndrome and autoimmune reactions -- Cytokines and/or artificial antigenpresenting cells have also been used to enhance killing potency of adoptively transferred NK cells, and thus potentially eliminate the need for KIR or KIR ligand mismatch. 17, 18 Several studies that employ adoptive transfer of resting or activated auto logous or allogeneic NK cells for children with cancer are underway. [19] [20] [21] [22] Increasing insights regarding the potential of these approaches will be available in the coming years.
Monoclonal antibody-based immunotherapy
Naked antibodies can mediate antitumour effects through a myriad of mechanisms ( Figure 2 ) including growth factor blockade (such as trastuzumab in HER2expressing tumours), death receptor agonism (such as lexatumumab targeting TRAILR2), induction of antibody dependent cellmediated cytotoxicity (ADCC, for example, rituxi mab, antiGD2) or blockade of immune inhibitory signals (antiCTLA4, antiPD1). Monoclonal antibodies targeting death agonists have not proceeded along the pharmaceutical development pipeline, despite signals of activity in paediatric solid tumours. 23 Therefore, most naked monoclonal antibodybased therapeutics cur rently under study in paediatric cancer augment host immune responses. 24 Monoclonal antibodies that target GD2 disialo ganglioside have been tested in numerous clinical trials in neuroblastoma during the past 25 years. GD2 is highly expressed on all neuroblastomas, and is also expressed on normal tissues in the central nervous system (CNS) and peripheral nerves, albeit at lower levels. 25 In patients with refractory neuroblastoma, early clinical studies with two murine antiGD2 monoclonal antibodies, 3F8 and 14.G2a, showed safety and some limited antitumour activity. 26, 27 To diminish immunogenicity, a chimeric monoclonal antibody derived from 14.G2a (dinutuxi mab, ch14.18) was developed. This agent showed a similar activity and safety profile in refractory neuro blastoma when combined with rhIL2 or GMCSF -agents coadministered to augment ADCC. 28 Ch14.18 also had promising effects on overall survival when administered as an adjuvant single agent following stan dard therapy for highrisk neuroblastoma. 29 In a pivotal random ized phase III study, patients with neuroblastoma who received autoHSCT plus isotretinoin plus ch14. 18 , GMCSF and rhIL2 demonstrated a significantly increased EFS and overall survival compared to patients receiving autoHSCT plus isotretinoin alone (EFS: 66% versus 46% P = 0.01; overall survival 86% versus 75% at 2 years, P = 0.02, respectively).
2 Sequential singlearm studies in with patients highrisk neuroblastoma that were treated with the 3F8 antiGD2 monoclonal antibody following autologous HSCT also demonstrated promis ing effects. 30 Together, this literature provides conclusive evidence that antiGD2 monoclonal antibody therapy should be considered an essential element in frontline therapy for patients with highrisk neuroblastoma.
Several challenges remain if we are to maximize the benefits and minimize the toxic effects of antiGD2 thera pies. In patients with bulk disease, antiGD2 mono clonal antibodies show limited activity and many chil dren with highrisk neuroblastoma cannot enter a minimal residual disease state. Hence, there is keen inter est in augmenting the potency of these agents, largely by modifying the function of effector cells that mediate ADCC (Figure 2 ). One approach involves generation of a fusion protein linking ch14.18 to rhIL2 (hu14.18 IL2), which activates NK cells through the IL2 recep tor. Hu14.18IL2 did not induce tumour shrinkage in children with bulk disease, but a 22% complete response rate was observed in children with disease burdens detectable only by MIBG (metaiodobenzylguanidine) therapy. 31 Interestingly, 29% of patients predicted to have increased NK cell reactivity based upon KIR-KIRligand mismatch showed objective responses or clini cal improvement whereas no responses were observed in those without KIR-KIRligand mismatch (P = 0.03), and there was a trend toward improved response rates in patients with an Fc receptor (FcR) polymorphism, which is predicted to mediate a morepotent ADCC effect. 32 Improved outcomes have also been observed in chil dren treated with 3F8 who had KIRligand mismatch. 33 Given this emerging evidence suggesting that NK cells are important mediators of antitumour effects of anti GD2 monoclonal antibodies, several studies are investi gating adoptive NK cell therapy to further augment antiGD2 potency. 34 Preclinical work has demonstrated that blockade of CD47-the ligand for the inhibitory signalling receptor SIRPα on macrophages-augments ADCC and can improve the efficacy of antibody therapies ( Figure 1 ).
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CD47 is expressed in many cancers and trials of antiCD47 monoclonal antibodies are planned, both as a single agent and in combination with tumourspecific antibodies aimed at inducing ADCC. Given the recent data demonstrating GD2 expression on osteosarcomas, 36 several groups are enrolling nonneuroblastoma GD2 positive paediatric patients with solid tumours onto trials incorporating antiGD2, including osteosarcoma and melanoma.
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Strategies are also underway to diminish the toxi city associated with antiGD2 therapy, in particular pain associated with the monoclonal antibody infusion, which is presumably due to complement activation and inflam mation targeting GD2+ peripheral nerves. A humanized antiGD2 (Hu14.18K322A) with a point mutation that prevents complement activation was shown to be safe with modest clinical activity in a phase I study; however, definitive results regarding whether this agent induces less pain than other antiGD2 agents will require further study. 37 Alternatively, an antiOacetyl GD2 monoclonal antibody has been developed that binds to a form of GD2 that is absent from peripheral nerves, but expressed at high levels on neuroblastoma cells. 25 Several other naked monoclonal antibodies target ing antigens expressed on paediatric leukaemias are approved for use in adults, but there is a paucity of con trolled clinical trial data to define their role in paedi atric malignancies. 38 For example, the antiCD20 mono clonal antibody rituximab mediates impressive improvements in outcomes when combined with chemo therapy for adults with Bcell lymphoma.
39 CD20 is expressed on mature Bcell leukaemias and lymphomas in children (including Burkitt lymphoma/leukaemia and some cases of diffuse, large Bcell lymphoma), but only limited studies have been conducted with rituximab in child hood cancer. 40 Rituximab has single agent activity in newly diagnosed Burkitt lymphoma and is safe when administered in combination with standard chemo therapies, but definitive evidence that adding rituximab to frontline regimens improves outcome is lacking. 40 Importantly rituximab has an established role in the treatment of children and adults with posttransplant lymphoproliferative disorder, 40 and several benign dis eases including immune thrombocytopenic purpura, 41 which are beyond the scope of this Review. Newer anti CD20 agents optimized for ADCC activity are likely to undergo study in children in the coming years. Similarly, the antiCD22 monoclonal antibody epratuzumab has been tested in children with BALL, and is safe and shows some single agent activity, but studies have not yet defined a clear role for this agent in the treatment of BALL. 35 Although we have emphasized agents that work by modulating the host immune system, it is important to note that monoclonal antibodies conjugated to toxins, drugs or radionuclides are also an important emerg ing class of therapeutics in paediatric cancer (Figure 2) . Antibody conjugates that have demonstrated activity in paediatric cancers include ibritumomab tiuextan (targeting CD20 in B cell lymphoma), inotuzumab ozogamycin and moxetumomab (targeting CD22 in BALL and Bcell lymphoma), gemtuzumab ozogami cin (targeting CD33 in AML) and brentuximab vendotin (targeting CD30 in Hodgkin lymphoma and anaplastic largecell lymphoma). [42] [43] [44] Bispecific antibodies Bispecific antibodies link a tumourtargeting domain to a domain that activates a receptor on an immune effec tor cell (Figure 2 ). An antiCD19/antiCD3 bispecific antibody (blinatumomab), which mediates an inter action between CD19+ on leukaemic blasts and CD3+ on T cells, is currently under study in BALL. 45 Clinical trials first tested this agent in adults with minimal resid ual BALL where a 78% complete response rate was reported. 46 Of note, essentially all patients on this study had chemorefractory disease. In a subsequent small study that enrolled children (n = 9) with relapse follow ing allogeneic HSCT, 67% of patients entered remission following blinatumomab therapy. 47 Response rates from a large phase I study of blinatumomab in children with relapsed BALL are awaited and a phase III trial testing blinatumomab in relapsed paediatric BALL is planned. 45 The dose limiting toxicity of this agent is cytokine release syndrome, which can be associated with neuro logical toxi city. 48, 49 Furthermore, recurrence following blinatumomab therapy has been associated with the loss of CD19 expression in some cases. 46 Other bispecific reagents are currently in clinical development in adults and are likely to be tested in children in the near future, including agents that augment NK cells to mediate anti tumour effects. Trispecific reagents that incorporate both T cell and NK cell engaging components with a tumour targeting domain or two tumourtargeting domains with a single immune effector cell engager are soon to be tested in clinical trials. 50 Checkpoint inhibitors Some antibody subclasses, such as IgG4, do not engage Fc receptors and can block access of the receptors to their natural ligands, which inhibits receptor signalling and does not induce ADCC. Checkpoint inhibitors are a new class of immunotherapeutics designed to block cell surface molecules expressed on T cells that transmit inhibitory signals (Figure 1 ). Ipilimumab (antiCTLA4) is the prototype and has been demonstrated to improve survival in patients with metastatic melanoma, albeit with significant autoimmune toxicity. 51 Ipilimumab has been tested in a phase I trial in children with cancer, but preliminary results did not report objective responses. 52 Interestingly, ipilimumab induced significant immune activation and autoimmune toxicity, providing proof ofprinciple that, similar to the situation in adults, chil dren harbour autoreactive T cells that can be 'turned on' by checkpoint inhibition. A second class of checkpoint inhibitors includes those that target PD1. Adult studies of antiPD1 monoclonal antibodies have demonstrated efficacy in a wide array of cancers with less toxicity than ipilimumab. 53 Clinical trials of antiPD1 have not yet been initiated in children with cancer, but are anticipated to open within the year.
Tumour vaccines
Seminal studies in the early 1990s elucidated the molecular targets of Tcell recognition on cancer cells and ushered in the modern era of immunotherapy for cancer. 54 Tumour vaccines targeting defined tumour antigens were among the first molecularly based immuno therapies tested. Animal models consistently demonstrated that tumour vaccines prevented tumour growth when administered before tumour inocula tion, but were less effective in the setting of established tumours. Clinical studies have largely confirmed this paradigm, concluding that tumour vaccines are safe, but not adequate to mediate regression of established tumours. 55 This situation likely relates to the multitude of factors contributing to immune escape that are not impacted by the vaccine per se (Box 1). Despite these challenges, some randomized studies have shown improvements in survival in patients with bulky tumours treated with tumour vaccines, leading to the first FDA approved tumour vaccine for men with metastatic hormone refractory prostate cancer. 56 Although tumour shrinkage was not observed, improved survival was attributed to diminished tumour growth rate. 57, 58 Beyond the inability of tumour vaccines to mediate cancer regression, other challenges have hampered rapid progress in this arena. Investigators have used a multitude of approaches to deliver vaccine therapies, from peptides administered with adjuvant to viral based vectors to dendritic cells. It remains unclear whether any approach is superior, and the array of therapeutics tested has made comparisons across platforms, diseases and tumour antigens difficult. Furthermore, to improve potency, investigators are administering tumour vaccines with other cancer therapies and immunotherapies, com pounding the complexities of comparing results across platforms. Finally, biological end points, such as Tcell responses, have not correlated closely with clinical out comes in tumour vaccine trials, making it difficult to define surrogate end points for vaccine efficacy. 59 Thus, although some single arm and randomized phase II studies of therapeutic tumour vaccines have demon strated promising results, 60, 61 definitive trials are lacking for most tumour vaccines.
Numerous single arm clinical trials of tumour vac cines have been conducted in children with cancer and several ongoing studies are underway (Table 1) , the results of which are awaited. Similar to the results in adults, paediatric cancer tumour vaccines are safe to administer, but tumour regression has been rarely observed. Because many paediatric cancers are aggres sive by nature, slowing tumour growth rate might not have meaningful clinical benefits. Despite these chal lenges, it remains plausible that tumour vaccines could provide an approach to diminish recurrence in high risk paediatric tumours, particularly given the minimal toxicity. Preliminary results were reported from one trial using tumour lysate pulsed dendritic cells plus autologous lymphocyte infusions with or without recombinant IL7 following standard upfront therapy in patients with metastatic or recurrent Ewing sarcoma and rhabdomyosarcoma. 62 Immune responses to auto logous tumour lysates were induced in approximately one third of patients, and intenttotreat analysis of the subset of patients enrolled at the time of a new diagno sis of meta static Ewing sarcoma or rhabdomyosarcoma showed 83% 5year overall survival and 54% 5year EFS, which is superior to previous outcomes reported for this population.
Adoptive T-cell therapy
Tumour-infiltrating lymphocytes Adoptive Tcell immunotherapy has shown activity in a small subset of cancers, with increasing evidence for efficacy and increasing experience in paediatrics. 3, 4 Fundamental factors driving development of adop tive Tcell immunotherapy for cancer is the evidence that T cells administered to receptive hosts can undergo multilog expansion, eradicate large tumour burdens and persist for months to years. 63, 64 Adoptive Tcell immunotherapy seeks to administer tumour reactive T cells with enhanced number and/or functionality. In most cases, cells are administered after lymphodeplet ing preparative regimens, since lymphopenia enhances expansion of adoptively transferred T cells. 65, 66 Adoptive Tcell immunotherapy products can be generated using a variety of different approaches, which we discuss on this basis of the method used to enrich for tumour s pecificity (Table 2) .
Adoptive transfer of tumour infiltrating lymphocytes (TILs) transfers T cells harvested from the tumour bed, which are then expanded ex vivo. TILs have shown impressive results in metastatic malignant melanoma, 67 but cannot be reliably generated from most tumour histo logies and have not been developed to target paedi atric cancers. Nonetheless, it is important to note that TILs were the first immunotherapy to mediate regres sion of large tumour burdens and some patients have remained disease free for many years after such therapy. 67 These encouraging results raise the prospect that bulky tumours and metastatic disease could be cured with Tcellbased immunotherapy. Furthermore, TILs can mediate significant antitumour effects in patients with CNS metastases, 68 indicating that systemic immuno therapies could also be used for immunotherapy of primary brain tumours. Studies of TILs have also provided insights into the molecules driving natural immune responses to cancer. These can be cat egorized into tissue differentiation antigens, cancertestis anti gens and more recently, mutated genes. One recent study demonstrated impressive results in one patient where nextgeneration sequencing identified a mutant tumour antigen driving expansion of tumour infiltrating lymphocytes, which mediated tumour regression upon adoptive transfer. 69 Recent studies emphasizing mutated genes as immunodominant tumour antigens raise fun damental questions regarding whether the low mutation rate observed in paediatric tumours 70 translates into diminished immuno genicity for paediatric cancers com pared to their adult counterparts, and this issue is likely to be addressed in greater depth in the coming years. 76 Thus, viral specific CTL are an effective treatment modality for viral infections occurring in immunocompromised hosts, and for PTLD occur ring in states of severe immuno suppression. Recent data demonstrates that they may also have activity in children and adults with EBVassociated lymphoma. 76 Given that a large fraction of patients treated with these cells received them following alloHSCT without complications related to GVHD, some groups are now attempting to use antigen selection and/or expansion to generate adoptive Tcell products target ing tumour antigens following alloHSCT to prevent l eukaemic relapse.
77
Genetically engineered TCR and CARs Experience using adoptive immunotherapy and geneti cally engineered Tcell products with specificity for tumourassociated antigens is increasing rapidly.
Transgenic Tcell receptors (TCRs) are structurally identi cal to native TCRs, and are major histocompati bility complex (MHC) restricted and their a pplicability is limited to patients who share their restricting HLA allele. Most transgenic TCRs assessed in clinical trials were derived from naturally occurring tumour r eactive TCRs that have been manipulated to enhance avidity before use in clinical studies. 78 While transgenic TCRs are not available to target the vast majority of paedi atric cancers, there is some emerging experience using this approach in NYESO1 expressing synovial sarcomas. 79 In the initial report, four of six patients treated for NYESO1+ synovial sarcoma had objec tive responses, and studies in children and adults are ongoing. 80 Although RNA expression of NYESO1 has been reported in a wide array of paediatric sarcomas, NYESO1 protein expression is limited to synovial sar comas; therefore, these studies are c urrently limited to patients with synovial sarcoma. 81 Chimeric antigen receptors (CARs) are nonnative recep tors that incorporate an MHC nonrestricted antigen binding domain with signalling domains designed to 'imitate' the downstream signalling of natural T cells. Early CAR trials incorporated the TCR zeta signal to activate T cells (firstgeneration CARs) whereas subsequent studies have used two downstream activation signals (second generation CARs, Figure 3 ) or three signals (third generation CARs). In 2007, Park et al. 82 reported treatment of six children with CARs targeting L1CAM (CD171) in patients with neuro blastoma. No toxicity was observed, however, the cells did not persist for prolonged periods and no objective responses were reported. In 2008, Pule et al. 83 reported results of a study of a first generation GD2CAR derived from the antiGD2 mAb, 14.G2a. Objective responses occurred in two out of eight patients with evaluable disease and longterm followup of 19 patients treated in this manner demonstrated continued complete responses in two out of 11 patients with evaluable disease and continued remission in four out of eight patients with no evident disease at the time of GD2CAR infu sion.
84 GD2CAR therapy had no evident shortterm or longterm toxicity and molecular evidence for lowlevel persistence of GD2CAR T cells was found in essentially all surviving patients, with the longest duration noted to be 192 weeks. Clinical trials are currently underway using a thirdgeneration GD2CAR, designed to enhance potency, as discussed below. 85, 86 In an effort to enhance expansion and persistence of CAR T cells, several groups have incorporated addi tional costimulatory endodomains, and a clinical study using CD19CAR T cells for treatment of lymphoma in adults confirmed enhanced expansion and persistence with these constructs. 87 Thus, modern CAR T cells that deliver at least two signals upon recognition of the tumour antigen are believed to be more potent on a per cell basis than native T cells or firstgeneration CAR expressing T cells. The first clinical results of CD19CAR therapy came from studies in adults where antitumour effects were reported in CD19expressing lymphomas and chronic lymphocytic leukaemia. [88] [89] [90] [91] More recent reports demonstrated that CD19CAR therapy medi ates very high response rates in BALL, both in chil dren 4, 92, 93 and adults. 94 Two large paediatric series of CD19CAR were reported. A phase I trial reported the use of CD19CAR T cells coexpressing TCR zeta plus CD28 (Figure 3 ) to 21 patients within 11 days of enrolment on study following a consistent preparative regimen incorporating cyclophosphamide and fludara bine. 4, 95 The study demonstrated feasibility of generating CD19CAR T cells meeting protocol prescribed doses in 90% of patients, and intenttotreat analysis of all patients enrolled revealed a 66.7% complete response rate with 70% of all patients with BALL rendered into a complete remission and in 60% of patients, there was no evidence of minimal residual neoplastic disease. Using a nonintenttotreat analysis and variable postcell harvest chemotherapy regimens, Maude et al. 93 reported a 90% complete remission rate in 30 patients with BALL treated with CD19CAR therapy. In this study, T cells were transduced with a lenti viral vector encoding a secondgeneration CD19CAR coexpressing TCR zeta plus 41BB (Figure 3) . In both studies, complete remis sions were observed in patients with disease that was refractory to standard chemotherapy, including a total of nine patients with primary chemorefractory disease. Both studies also observed traffick ing of CD19CAR cells into the cerebrospinal fluid and clearance of CNS leukaemia; toxicity in both studies was primarily related to cytokinerelease syndrome. 96 Despite the similarities, differential persistence of the genetically engineered T cells was noted. CD19CAR cells expressing the CD28 endodomain showed peak expansion around day 14 and then disappeared with recovery of normal B cells within 60 days. 4 By contrast, CD19CAR cells expressing the 41BB endodomain persisted for several months with persistent Bcell aplasia. 93 It remains to be seen whether CD19CAR therapy can cure refractory BALL and whether this varies depending upon the costimulatory domain and persistence of the genetically engineered cells. This important issue will be addressed in future studies. In another study, Cruz et al. 97 administered donorderived virusspecific T cells expressing CD19 CAR after alloHSCT. GVHD was not observed and a complete response was reported in one of two patients treated with measurable BALL. In summary, the lit erature demon strates high response rates using second generation CD19CAR therapy for chemo refractory BALL and future studies will focus on improving the safety of the therapy, improving exportability and deter mining how best to integrate this novel therapeutic into standard regimens for BALL. Several studies using CD19CAR therapies are currently open and enrolling children with refractory Bcell malignancies.
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Challenges
Immune escape It is becoming increasingly clear that immune pressure can select antigenloss variants as a means of immune escape. This has been most notable in the context of CD19directed treatments for BALL. Although BALL is universally CD19positive at presentation, and CD19 apparently contributes to the survival of malignant B lymphoblasts, 101 CD19negative BALL emerges in a signifi cant number of patients following blinatu momab or CD19CAR cell therapy. 3, 4, 46, 93 Investigators are attempting to tackle this problem by targeting other molecules, and in the context of CARs for BALL, a CD22directed CAR is soon to enter the clinic that demonstrates similar potency as the CD19CARs in pre clinical models. 102 Bivalent therapeutics are also likely to be tested (termed tandem CARs) that seem effective in preclinical models at mitigating selection of antigen loss variants. 103 For therapies using MHCrestricted T cells, immune escape can also occur via loss of antigen expression, or downregulation of MHC, which is com monly observed. 9 For this reason, simultaneous targeting using T cells and NK cells has been considered, because MHC downregulation as a means of escape from Tcell mediated responses would enhance susceptibility to NKmediated killing.
Toxicity
Toxic effects associated with immunebased therapies are distinct from toxic effects resulting from cytotoxic regimens, and can be divided into antigenspecific and antigen nonspecific toxicities. Antigenspecific toxici ties occur when immune responses are directed toward noncancer tissues expressing the targeted antigen. Pain associ ated with antiGD2 therapy, Bcell depletion associ ated with CD19 directed therapies, and immune mediated events occurring in patients treated with checkpoint inhibitors fall into this class. Autoimmune toxicity is especial ly common following treatment with ipilimumab, and occurs in over 50% of children. 52 The severity of autoimmune toxicity associated with immuno therapy varies greatly depending upon the tissue targeted and the efficacy of clinical intervention. For example, autoimmune colitis in early adult studies of ipilimumab was an important cause of morbidity, but with improved clinical surveillance and management, this adverse effect is now largely controlled. By contrast, hypophysitis associated with i pilimumab usually leads to lifelong panhypopituitarism. 104 In the context of adoptive Tcell therapies, auto immune antigenspecific toxicity can be severe and even fatal. Two separate clinical trials using T cells targeting the cancer testis antigen MAGEA3 in adults resulted in fatal toxi city owing to previously unappreciated expres sion of the target or a crossreactive peptide on cardiac and neural tissues. 105, 106 For this reason, firstinhuman adoptive Tcell therapies must carefully consider the potential for unexpected ontarget and offtumour toxi city because the severity of the effect is predicted to increase as the immuno therapeutics acquires enhanced potency. One approach used when the risk of such toxi cities is deemed to be high, is to incorporate a suicide domain into the receptors, which allows one to rapidly eradicate the genetically engineered cells. Proofof principle for this approach has been demonstrated in the context of allogeneic DLI for GVHD, and such a vector is currently in use with c himeric antigen receptors targeting GD2 on paediatric cancers. 107 Alternatively, platforms that transiently express the targeted receptor as a means to minimize the risk of toxicity are in early phase trials.
The second major class of toxicities associated with immunotherapies for treating cancer is the cytokine release syndrome. Here, supraphysiologic levels of immune cell activation lead to high levels of inflam matory cytokines, which mediate a variety of toxic effects and can result in multisystem failure and death. Cytokinerelease syndrome was first observed following treatment with monoclonal antibodies for cancer and has been observed in the context of adoptive cellbased therapies, especially those using secondgeneration and thirdgeneration CARs. 108 The syndrome is characterized by fever and constitutional symptoms that can progress to cardiac, renal, hepatic or neurological dysfunction. In noncontrolled trials, treatment with antiIL6R monoclonal antibody and/or corticosteroids effectively reverses the syndrome. 108 Given the potential severity of this syndrome as well as its eminent treatability, it is imperative that clear guidelines for grading and treat ment of cytokinerelease syndrome are incorporated into early phase immunotherapy trials where this adverse effect is likely to occur.
New targets
Recent advances in genetic engineering have allowed the generation of monoclonal antibodies and/or T cells bearing an almost infinite array of specificities, and improved understanding of immune cell biology renders optimism that potent immune responses can be induced in most cancer patients. However, a fundamental barrier to progress is a paucity of immune targets for cancer in general and paediatric cancers in particular. Optimal immune targets should be highly expressed on tumour tissues and not expressed on normal tissues, and a role for the target in oncogenesis is preferred, albeit not required. Beyond mutated tumour antigens, which are individualspecific, tumourspecific targets are rare. Alternatives include targeting molecules expressed on tumour cells and nonvital tissues, such as CD19. Although CD19 targeted therapies induce profound Bcell depletion, this is manageable in the shortterm and even potentially in the longterm. 89 For Tcell malig nancies, myeloid neoplasms and solid tumours defin ing targets restricted to tumour and nonvital tissues has proven difficult. Studies are underway using novel genomic approaches to identify targets for immuno therapy of paediatric cancers and results of these studies are anxiously awaited. 109 Another possibility is to use combinatorial targeting, especially using CARs, which could allow one to target pairs of antigens on tumours when such pairs are not expressed on normal tissues. 110 Tumours can also express aberrant glyco sylation pat terns that could be exploited with some mono clonal antibodies or their derivatives, but would not be identified using genomic approaches. An important consideration is that targeting of tumours using anti bodybased approaches including CAR T cells requires cell surface expression, thus excluding a large group of intracellular proteins that are differentially expressed in tumours. For these antigens, Tcell receptorbased approaches are required. Continued success in the field of immunotherapy for paediatric cancer will require a concerted and creative effort by the paediatric oncology community to identify optimal targets for this exciting new class of therapeutics.
Technical challenges
Other challenges involve the export of immunotherapies out of major academic centres. This is particularly rel evant to cellbased immunotherapies for which special ized facilities for production of cells is needed. Owing to the need for these specialized facilities, it is anticipated that such therapies could incur substantial cost. For this reason, 'offtheshelf ' immunotherapies, such as bispecific antibodies that can engage host immune cells without the need for ex vivo cell generation, might be preferred if response rates and toxicities are similar. It remains to be seen whether such offtheshelf reagents will be a potent as cellbased immunotherapy, and whether a lack of persistent immune pressure induced with antibody versus cellular therapies will impact overall outcomes.
Conclusions
Immunotherapy is one of the most rapidly moving fields in cancer therapy. The momentum is driven by evidence that immunebased killing can eradicate chemoresis tant tumour cells combined with dramatic technologi cal advances that allow efficient engineering of complex monoclonal antibodies and Tcellbased therapeutics and effective ex vivo and in vivo expansion of Tcell and NK effector populations. Current trials tend to focus on one modality, but it is anticipated that combinations of immunebased therapies will be additive or even syner gistic and, therefore, combinatorial regimens are likely to emerge during the next decade. The paediatric onco logy community will play a vital role in bringing these powerful therapeutics to help treat childhood cancer, by identifying novel targets, developing algorithms for diagnosis and management of immunotherapyrelated toxicities and through identifying optimal approaches for incorporating this new class of therapeutics into standard treatment regimens to maximize cure and minimize toxicities.
Review criteria
Information for this article was obtained by searching the PubMed database without restriction on publication dates. The following search terms included "immunotherapy" and "paediatric cancer". Salient preliminary results published in abstract form have been included, but a comprehensive search of published abstracts was not performed. Only articles published in English were considered.
FOCUS ON PAEDIATRIC CANCER
